Evidence map›Paper›PMID 41797506›Full record

ReviewTherapeutic delivery2026

The potential of organic nanoparticles and plant-derived adjuvants for vaccine design.

V A Márquez-Escobar, A Miranda-López, S Vimolmangkang, S Rosales-Mendoza

Abstract readReview
In one paragraph

Review in Therapeutic delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

V A Márquez-EscobarBiotechnology Section, Center for Research in Health Science and Biomedicine, Autonomous University of San Luis Potosí, San Luis Potosí, Mexico.ORCID 0009-0000-6970-6130
A Miranda-LópezBiotechnology Section, Center for Research in Health Science and Biomedicine, Autonomous University of San Luis Potosí, San Luis Potosí, Mexico.ORCID 0009-0002-2630-9076
S VimolmangkangDepartment of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.ORCID 0000-0002-1705-6217
S Rosales-MendozaBiotechnology Section, Center for Research in Health Science and Biomedicine, Autonomous University of San Luis Potosí, San Luis Potosí, Mexico.ORCID 0000-0003-2569-7329

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organic nanoparticles (NPs) are nanoscale entities composed of natural or synthetic carbon-based compounds. In biomedicine, particularly in vaccine development, their properties facilitate antigen loading, stabilization, and delivery, while exerting immunostimulatory effects that enhance immune responses. Compared to inorganic NPs, organic NPs often exhibit higher safety profiles, greater chemical versatility for functionalization, and superior mucoadhesive properties. Over the past three decades, organic NP-based nanovaccines have been increasingly explored, generating preclinical evidence demonstrating ability to induce robust immune responses and confer immunoprotection. Within this context, plant-derived compounds have attracted growing interest due to their chemical diversity and broad spectrum of bioactivities, including immunostimulatory effects, making them promising candidates as vaccine adjuvants. The data presented in this review were derived from review of peer-reviewed literature identified through searches on PubMed, Scopus, and ScienceDirect, covering studies published between 2000 and 2025, with earlier foundational studies included. This review discusses the application of organic NPs in nanovaccine platforms, detailing key properties, advantages, and the promising vaccine prototypes reported in the literature. Special attention is given to the potential of plant-derived compounds as adjuvants, highlighting their role in optimizing organic NP-based nanosystems for vaccine delivery, while providing insights into key design considerations for developing effective vaccines.

Indexed as

Adjuvants, ImmunologicAdjuvants, VaccineNanoparticlesPlantsVaccinesAnimalsHumansNanovaccinesVaccine DevelopmentAdjuvants, ImmunologicAdjuvants, VaccineNanovaccinesVaccinesadjuvantdelivery systemlipid nanoparticlesliposomesmicellesOrganic nanoparticlesphytochemicalsPLGA

Identifiers

PMID41797506
PMCPMC12977262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.